The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis
Open Access
- 15 April 2020
- Vol. 9 (4), 972
- https://doi.org/10.3390/cells9040972
Abstract
YAP and TAZ are intracellular messengers communicating multiple interacting extracellular biophysical and biochemical cues to the transcription apparatus in the nucleus and back to the cell/tissue microenvironment interface through the regulation of cytoskeletal and extracellular matrix components. Their activity is negatively and positively controlled by multiple phosphorylation events. Phenotypically, they serve an important role in cellular plasticity and lineage determination during development. As they regulate self-renewal, proliferation, migration, invasion and differentiation of stem cells, perturbed expression of YAP/TAZ signaling components play important roles in tumorigenesis and metastasis. Despite their high structural similarity, YAP and TAZ are functionally not identical and may play distinct cell type and differentiation stage-specific roles mediated by a diversity of downstream effectors and upstream regulatory molecules. However, YAP and TAZ are frequently looked at as functionally redundant and are not sufficiently discriminated in the scientific literature. As the extracellular matrix composition and mechanosignaling are of particular relevance in bone formation during embryogenesis, post-natal bone elongation and bone regeneration, YAP/TAZ are believed to have critical functions in these processes. Depending on the differentiation stage of mesenchymal stem cells during endochondral bone development, YAP and TAZ serve distinct roles, which are also reflected in bone tumors arising from the mesenchymal lineage at different developmental stages. Efforts to clinically translate the wealth of available knowledge of the pathway for cancer diagnostic and therapeutic purposes focus mainly on YAP and TAZ expression and their role as transcriptional co-activators of TEAD transcription factors but rarely consider the expression and activity of pathway modulatory components and other transcriptional partners of YAP and TAZ. As there is a growing body of evidence for YAP and TAZ as potential therapeutic targets in several cancers, we here interrogate the applicability of this concept to bone tumors. To this end, this review aims to summarize our current knowledge of YAP and TAZ in cell plasticity, normal bone development and bone cancer.Keywords
Funding Information
- Austrian Science Fund (29773-B28)
This publication has 261 references indexed in Scilit:
- Lysyl Oxidase Is Downregulated by the EWS/FLI1 Oncoprotein and Its Propeptide Domain Displays Tumor Supressor Activities in Ewing Sarcoma CellsPLOS ONE, 2013
- A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β-catenin signallingThe EMBO Journal, 2012
- Mitochondrial Complex III ROS Regulate Adipocyte DifferentiationCell Metabolism, 2011
- A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sitesGenes, Chromosomes and Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcomaOncogene, 2010
- Kibra Functions as a Tumor Suppressor Protein that Regulates Hippo Signaling in Conjunction with Merlin and ExpandedDevelopmental Cell, 2010
- Mesenchymal Stem Cell Features of Ewing TumorsCancer Cell, 2007
- Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1Proceedings of the National Academy of Sciences of the United States of America, 2007
- Transforming properties of YAP , a candidate oncogene on the chromosome 11q22 ampliconProceedings of the National Academy of Sciences of the United States of America, 2006